The Combined Antibiotic Therapy for Carbapenem Resistant Klebsiella Pneumoniae
How to Optimize the Combined Antibiotic Therapy for Carbapenem Resistant Klebsiella Pneumoniae
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
- Collect the BALF from patients diagnosed with CRKP infection in surgical intensive care unit(SICU)of Shanghai 10th people's hospital.
- Separate and purify the BALF. Divide each CRKP into four treatment groups based on meropenem.
3.1 By checkerboard method and microdilution broth method,get the minimal inhibitory concentration (MICS) of two antibiotics,then calculate the fractional inhibitory concentration (FIC) index according to MIC results.
3.2 Observe the effect of two antibiotics on the growth of CRKP by TKA.
4.By the above two invitro experiments, analyze the data of the experimental results and get the best combination therapy based on carbapenems.
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Early Phase 1
Contacts and Locations
Study Contact
Study Contact
- Name: Ma Lao, master
- Phone Number: 8613532437896
- Email: 13532437896@163.com
Study Locations
-
-
Shanghai
-
Shanghai, Shanghai, China, 201300
- Recruiting
- Shanghai 10th People's Hospital
-
Contact:
- Huanlong Qin, director
- Phone Number: 18917683138
- Email: wangsheng@tongji.edu.cn
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- age from 18 to 90.
- infected with CRKP firstly .
Exclusion Criteria:
- APACHE II score > 35
- Vital signs are unstable
- Unable to tolerate fiberoptic bronchoscopy
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: only meropenem therapy,
this group is only meropenem therapy as a single antibiotic treatment
|
Fosfomycin and meropenem
Other Names:
Tigecycline and meropenem
Other Names:
Polymyxin B and meropenem
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
the fractional inhibitory concentration index (FICI)
Time Frame: 24hours-36hours
|
By checkerboard method and microdilution broth method,get the minimal inhibitory concentration (MICS) of two antibiotics,then calculate the fractional inhibitory concentration (FIC) index according to MIC results. Evaluation index: FIC=0.5 , coordinating effect. 0.5 < FIC <1, adding effect; 1 < FIC <2, irrelevant. |
24hours-36hours
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
the time-kill assay (TKA)
Time Frame: 36hours-48hours
|
According to the Clinical and Laboratory Standards Institute,observe the changes of bacterial growth over time after different combination therapy.
|
36hours-48hours
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Li Hua, master, Shanghai 10th People's Hospital
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- STPH-ICU-002
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.